Geert M. Verleden
Research Subjects
Geert M. Verleden has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Van Raemdonck
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
16 shared publications - Bart M. Vanaudenaerde
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
6 shared publications Lieven J. Dupont
Departments of Respiratory Disease and Thoracic Surgery, and Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium
5 shared publicationsR. Vos
5 shared publications- T. Lerut
Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
5 shared publications Johan Vanhaecke
3 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S43
EPS4.01 Microbial community composition in explanted cystic fibrosis lungs
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S43
EPS4.01 Microbial community composition in explanted cystic fibrosis lungs
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , S45-S46
Long-Term Effects of Preemptive Azithromycin Therapy for CLAD After Lung Transplantation: Post Hoc Analysis of a Randomized Controlled Trial
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , S45-S46
Long-Term Effects of Preemptive Azithromycin Therapy for CLAD After Lung Transplantation: Post Hoc Analysis of a Randomized Controlled Trial
- Open Access
- 1 July 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 17 (suppl_1) , S26-S27
O-099LUNG TRANSPLANTATION WITH GRAFTS RECOVERED FROM EUTHANASIA DONORS
Donors after circulatory death (DCDs) enlarge the lung donor pool. We reviewed outcome in recipients transplanted with lungs recovered from controlled DCDs Category-5 (euthanasia donors). Between January 2007 and December 2012, 47/350 (13.4%) patients received pulmonary grafts from controlled DCDs, including 6 (1.7%) after euthanasia in accordance with state legislation and approval by Ethics Committee. Patients suffered from an unbearable neuromuscular (n = 3) or neuropsychiatric (n = 3) disorder with explicit wish to donate organs. Euthanasia was executed by an independent physician in a room adjacent to the operating room in the absence of the retrieval team. Six recipients (2M–4M; median [range] age: 51 [30-59] years) underwent bilateral lung transplantation for emphysema (n = 3), pulmonary fibrosis (n = 2), and BOS (n = 1). Waiting time was 436 [195-507] days. In contrast to other DCD categories, pre-arrest agonal period was absent. Warm ischaemic time between cardiac arrest and cold Perfadex® pulmonary flush was 13 ± 3 min. Total ischaemic time until reperfusion of the graft was 329 [225-427] min for first lung and 478 [346-603] min for second lung. No primary graft dysfunction grade 3 was present beyond T24. One recipient died after 3 months in ICU from an unrelated cardiac problem. Remaining patients were extubated after 2 [1-5] days and discharged from ICU after 7 [2-10] days and from hospital after 27 [23-36] days. FEV1 and FVC increased from 20 [15-57]% and 59 [51-66]% pre-transplant to 85 [61-94]% and 75 [54-80]% at the time of hospital discharge, respectively; (P < 0.01). Follow up was 37 [1-66] months. Actuarial survival and freedom from BOS grade 1 at 1, 3, and 5 years conditional to hospital discharge was 100%, 100%, and 100% and 100%, 100%, and 80%, respectively. Euthanasia donors accounted for 12.8% of all lung DCDs. Immediate post-transplant graft function and long-term outcome in recipients was excellent. More euthanasia donors are to be expected with more public awareness. All authors have declared no conflicts of interest.
- 1 July 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 17 (suppl_1) , S26-S27
Open AccessO-099LUNG TRANSPLANTATION WITH GRAFTS RECOVERED FROM EUTHANASIA DONORS
Donors after circulatory death (DCDs) enlarge the lung donor pool. We reviewed outcome in recipients transplanted with lungs recovered from controlled DCDs Category-5 (euthanasia donors). Between January 2007 and December 2012, 47/350 (13.4%) patients received pulmonary grafts from controlled DCDs, including 6 (1.7%) after euthanasia in accordance with state legislation and approval by Ethics Committee. Patients suffered from an unbearable neuromuscular (n = 3) or neuropsychiatric (n = 3) disorder with explicit wish to donate organs. Euthanasia was executed by an independent physician in a room adjacent to the operating room in the absence of the retrieval team. Six recipients (2M–4M; median [range] age: 51 [30-59] years) underwent bilateral lung transplantation for emphysema (n = 3), pulmonary fibrosis (n = 2), and BOS (n = 1). Waiting time was 436 [195-507] days. In contrast to other DCD categories, pre-arrest agonal period was absent. Warm ischaemic time between cardiac arrest and cold Perfadex® pulmonary flush was 13 ± 3 min. Total ischaemic time until reperfusion of the graft was 329 [225-427] min for first lung and 478 [346-603] min for second lung. No primary graft dysfunction grade 3 was present beyond T24. One recipient died after 3 months in ICU from an unrelated cardiac problem. Remaining patients were extubated after 2 [1-5] days and discharged from ICU after 7 [2-10] days and from hospital after 27 [23-36] days. FEV1 and FVC increased from 20 [15-57]% and 59 [51-66]% pre-transplant to 85 [61-94]% and 75 [54-80]% at the time of hospital discharge, respectively; (P < 0.01). Follow up was 37 [1-66] months. Actuarial survival and freedom from BOS grade 1 at 1, 3, and 5 years conditional to hospital discharge was 100%, 100%, and 100% and 100%, 100%, and 80%, respectively. Euthanasia donors accounted for 12.8% of all lung DCDs. Immediate post-transplant graft function and long-term outcome in recipients was excellent. More euthanasia donors are to be expected with more public awareness. All authors have declared no conflicts of interest.
- 1 January 2011
- Vol. 73, 41-63
Lung transplantation for respiratory failure; Belgium amongst the world leaders.
Lung transplantation is a life-saving treatment option in carefully selected patients with end-stage lung disease. Life expectancy after this form of treatment has progressively increased with a current survival of 90% after 1 year, 70% after 5 years, and 50% after 10 years in experienced centers. Apart from a survival benefit, this treatment aims to improve the quality of life. Bilateral lung transplantation is the type of operation that is performed most frequently because of superior survival results, especially when chronic rejection develops. Single lung transplantation is now reserved for older patients with pulmonary fibrosis. Heart-lung transplantation is rarely done, only in patients with Eisenmenger's syndrome or complex congenital heart disease. Belgium is one of the world leaders in terms of number of deceased organ donors with a lung recovery rate of about 35%. With a total of 8.3 lung transplants per million population, Belgium is currently the number 1 in the world. The procedure nowadays is performed in 4 University Hospitals (UA-KUL-ULB-UCL) in the country. Between 1983 and 2009, nearly 1000 proedures were performed. The most common indication was emphysema, followed by cystic fibrosis, pulmonary fibrosis, pulmonary arterial hypertension, and Eisenmenger's syndrome. Further application of this treatment option is hampered by several problems such as donor organ shortage, primary graft dysfunction, chronic rejection presenting as bronchiolitis obliterans syndrome, and side effect of chronic immunosuppression. In the Laboratory for Experimental Thoracic Surgery and the Laboratory for Pneumology at the Katholieke Universiteit Leuven, intensive research is done by our group looking for new methods to increase the lung donor pool and to prevent and to treat chronic rejection.
- 1 January 2011
- Vol. 73, 41-63
Lung transplantation for respiratory failure; Belgium amongst the world leaders.
Lung transplantation is a life-saving treatment option in carefully selected patients with end-stage lung disease. Life expectancy after this form of treatment has progressively increased with a current survival of 90% after 1 year, 70% after 5 years, and 50% after 10 years in experienced centers. Apart from a survival benefit, this treatment aims to improve the quality of life. Bilateral lung transplantation is the type of operation that is performed most frequently because of superior survival results, especially when chronic rejection develops. Single lung transplantation is now reserved for older patients with pulmonary fibrosis. Heart-lung transplantation is rarely done, only in patients with Eisenmenger's syndrome or complex congenital heart disease. Belgium is one of the world leaders in terms of number of deceased organ donors with a lung recovery rate of about 35%. With a total of 8.3 lung transplants per million population, Belgium is currently the number 1 in the world. The procedure nowadays is performed in 4 University Hospitals (UA-KUL-ULB-UCL) in the country. Between 1983 and 2009, nearly 1000 proedures were performed. The most common indication was emphysema, followed by cystic fibrosis, pulmonary fibrosis, pulmonary arterial hypertension, and Eisenmenger's syndrome. Further application of this treatment option is hampered by several problems such as donor organ shortage, primary graft dysfunction, chronic rejection presenting as bronchiolitis obliterans syndrome, and side effect of chronic immunosuppression. In the Laboratory for Experimental Thoracic Surgery and the Laboratory for Pneumology at the Katholieke Universiteit Leuven, intensive research is done by our group looking for new methods to increase the lung donor pool and to prevent and to treat chronic rejection.
- Open Access
- 31 August 2010
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 19 (117) , 212
Endoscopy: a clinical state of the art
- 31 August 2010
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 19 (117) , 212
Open AccessEndoscopy: a clinical state of the art
- Open Access
- 22 March 2010
- Published by Springer Nature in Respiratory Research
- Vol. 11 (1) , 35
Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD
Dendritic cells (DC) linking innate and adaptive immune responses are present in human lungs, but the characterization of different subsets and their role in COPD pathogenesis remain to be elucidated. The aim of this study is to characterize and quantify pulmonary myeloid DC subsets in small airways of current and ex-smokers with or without COPD.
- 22 March 2010
- Published by Springer Nature in Respiratory Research
- Vol. 11 (1) , 35
Open AccessSelective accumulation of langerhans-type dendritic cells in small airways of patients with COPD
Dendritic cells (DC) linking innate and adaptive immune responses are present in human lungs, but the characterization of different subsets and their role in COPD pathogenesis remain to be elucidated. The aim of this study is to characterize and quantify pulmonary myeloid DC subsets in small airways of current and ex-smokers with or without COPD.
- Open Access
- 12 August 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (9) , 1911-1920
The Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation
- 12 August 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (9) , 1911-1920
Open AccessThe Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation
- 1 October 2007
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (8) , 2659-2662
The Importance of Lymphocytes in Lung Ischemia-Reperfusion Injury
- 1 October 2007
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (8) , 2659-2662
The Importance of Lymphocytes in Lung Ischemia-Reperfusion Injury
- Open Access
- 1 May 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (5) , 1278-1287
Transient Airway Colonization Is Associated with Airway Inflammation After Lung Transplantation
- 1 May 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (5) , 1278-1287
Open AccessTransient Airway Colonization Is Associated with Airway Inflammation After Lung Transplantation
- 1 September 2006
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 174 (5) , 566-570
Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Bronchiolitis Obliterans Syndrome
Rationale: Bronchiolitis obliterans syndrome (BOS) remains the leading cause of death after lung transplantation. Treatment is difficult, although azithromycin has recently been shown to improve FEV1. The exact mechanism of action is unclear. Hypotheses: (1) Azithromycin reduces airway neutrophilia and interleukin (IL)-8 and (2) airway neutrophilia predicts the improvement in FEV1. Methods: Fourteen lung transplant patients with BOS (between BOS 0-p and BOS 3) were treated with azithromycin, in addition to their current immunosuppressive treatment. Before and 3 mo after azithromycin was introduced, bronchoscopy with bronchoalveolar lavage (BAL) was performed for cell differentiation and to measure IL-8 and IL-17 mRNA ratios. Results: The FEV1 increased from 2.36 (± 0.82 L) to 2.67 L (± 0.85 L; p = 0.007), whereas the percentage of BAL neutrophilia decreased from 35.1 (± 35.7%) to 5.7% (± 6.5%; p = 0.0024). There were six responders to azithromycin (with an FEV1 increase of > 10%) and eight nonresponders. Using categorical univariate linear regression analysis, the main significant differences in characteristics between responders and nonresponders were the initial BAL neutrophilia (p < 0.0001), IL-8 mRNA ratio (p = 0.0009), and the postoperative day at which azithromycin was started (p = 0.036). There was a significant correlation between the initial percentage of BAL neutrophilia and the changes in FEV1 after 3 mo (r = 0.79, p = 0.0019). Conclusion: Azithromycin significantly reduces airway neutrophilia and IL-8 mRNA in patients with BOS. Responders have a significantly higher BAL neutrophilia and IL-8 compared with nonresponders and had commenced treatment earlier after transplantation. BAL neutrophilia can be used as a predictor for the FEV1 response to azithromycin.
- 1 September 2006
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 174 (5) , 566-570
Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Bronchiolitis Obliterans Syndrome
Rationale: Bronchiolitis obliterans syndrome (BOS) remains the leading cause of death after lung transplantation. Treatment is difficult, although azithromycin has recently been shown to improve FEV1. The exact mechanism of action is unclear. Hypotheses: (1) Azithromycin reduces airway neutrophilia and interleukin (IL)-8 and (2) airway neutrophilia predicts the improvement in FEV1. Methods: Fourteen lung transplant patients with BOS (between BOS 0-p and BOS 3) were treated with azithromycin, in addition to their current immunosuppressive treatment. Before and 3 mo after azithromycin was introduced, bronchoscopy with bronchoalveolar lavage (BAL) was performed for cell differentiation and to measure IL-8 and IL-17 mRNA ratios. Results: The FEV1 increased from 2.36 (± 0.82 L) to 2.67 L (± 0.85 L; p = 0.007), whereas the percentage of BAL neutrophilia decreased from 35.1 (± 35.7%) to 5.7% (± 6.5%; p = 0.0024). There were six responders to azithromycin (with an FEV1 increase of > 10%) and eight nonresponders. Using categorical univariate linear regression analysis, the main significant differences in characteristics between responders and nonresponders were the initial BAL neutrophilia (p < 0.0001), IL-8 mRNA ratio (p = 0.0009), and the postoperative day at which azithromycin was started (p = 0.036). There was a significant correlation between the initial percentage of BAL neutrophilia and the changes in FEV1 after 3 mo (r = 0.79, p = 0.0019). Conclusion: Azithromycin significantly reduces airway neutrophilia and IL-8 mRNA in patients with BOS. Responders have a significantly higher BAL neutrophilia and IL-8 compared with nonresponders and had commenced treatment earlier after transplantation. BAL neutrophilia can be used as a predictor for the FEV1 response to azithromycin.